Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
AVEO Pharmaceuticals Inc. has 1 pending office action currently active in the Biotechnology & Pharmaceuticals technology area. This single action is being handled by 1 distinct examiner within 1 distinct art unit, representing a highly concentrated prosecution environment. For the practitioner, this means the entire pending portfolio at this stage is subject to the specific scrutiny of one individual and one specialized unit.
The busiest examiner identified is HOLTZMAN, KATHERINE ANN, who is assigned the 1 pending office action. Since there is only 1 distinct examiner involved, the prosecution path is entirely dependent on this examiner's specific requirements and the practices of the 1 distinct art unit. This concentration allows for a focused communication strategy, as there are no other pending actions or examiners to coordinate with across the portfolio.
With only a single pending action, the immediate administrative burden is low, but the strategic importance of this matter is high. The practitioner must tailor their response specifically to the expectations of HOLTZMAN, KATHERINE ANN. Success in the Biotechnology & Pharmaceuticals field will determine the immediate progress of the company's efforts, requiring a precise and persuasive argument to move the case forward.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOLTZMAN, KATHERINE ANN | 1 | 64.8% | +59.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18667500 | COMBINATION THERAPY FOR TREATMENT OF CANCER | HOLTZMAN, KATHERINE ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18667500 | COMBINATION THERAPY FOR TREATMENT OF CANCER | HOLTZMAN, KATHERINE ANN | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18667500 | COMBINATION THERAPY FOR TREATMENT OF CANCER | HOLTZMAN, KATHERINE ANN | 1646 | §101§102§103§112 | Non-Final OA | — | Pending | May 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAVEO Pharmaceuticals Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Katherine Ann Holtzman has the most, with 1 of AVEO Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
